CD63 and benign prostatic hyperplasia: Using either CD9, CD63 or CD81 antibodies to capture S‐EVs, LPCa has more abundance circulating S‐EVs in comparison with either BPH or AdvPCa samples (Figure 1d, *P < 0.05, **P < 0.01, ***P < 0.001).